Related Experiment Video
Updated: Aug 14, 2026
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Brain SPECT imaging in multiple system atrophy
1Parkinson Institute, Instituti Clinici di Perfezionamento, Milan, Italy.
Abstract:
Clinical diagnosis of multiple system atrophy (MSA) relays on signs and symptoms that are often difficult to identify particularly at early stage. Indeed neuropathological studies have demonstrated that MSA is the first cause of misdiagnosis in a cohort of patients presenting with parkinsonian features. Dopamine transporter imaging (DAT) shows striatal decrements in both MSA and Parkinson's disease (PD) making it not sensitive for differential diagnosis. Studies of dopamine D2 receptors with IBZM may help revealing striatal degeneration but a large overlap exist particularly if PD patients with advanced disease are included. We have measured brain flow with technetium-99m ethyl cysteinate dimer (ECD-SPECT) in 36 MSA patients and compared it with 43 PD and 39 age-matched controls. Using Statistical Parametric Mapping (SPM99) we found areas of significant reduced perfusion in the striatum, brain stem and cerebellum in MSA compared to the other groups. We believe that ECD-SPECT imaging may offer significant advantages compared to other imaging techniques in the assessment of neuronal degeneration in MSA and may help the clinician in the diagnostic characterization of patients presenting with atypical parkinsonism.
Insights
Technetium-99m ethyl cysteinate dimer single-photon emission computed tomography (ECD-SPECT) effectively identifies brain perfusion deficits in multiple system atrophy (MSA). This imaging technique aids in distinguishing MSA from Parkinson's disease (PD) and other parkinsonian syndromes.
Area of Science:
- Neuroimaging
- Neurology
- Nuclear Medicine
Background:
- Clinical diagnosis of multiple system atrophy (MSA) is challenging due to subtle early symptoms, leading to frequent misdiagnosis, particularly when compared to Parkinson's disease (PD).
- Existing imaging techniques like dopamine transporter (DAT) imaging and dopamine D2 receptor studies (IBZM) have limitations in differentiating MSA from PD, especially in advanced stages.
Purpose of the Study:
- To evaluate the utility of technetium-99m ethyl cysteinate dimer (ECD-SPECT) imaging in assessing brain perfusion.
- To differentiate between patients with multiple system atrophy (MSA), Parkinson's disease (PD), and healthy controls.
Main Methods:
- Brain perfusion was measured using ECD-SPECT in 36 MSA patients, 43 PD patients, and 39 age-matched controls.
- Statistical Parametric Mapping (SPM99) was employed to analyze regional cerebral blood flow differences between the groups.
Main Results:
- ECD-SPECT revealed significant reductions in brain perfusion within the striatum, brain stem, and cerebellum in MSA patients compared to both PD patients and controls.
- These perfusion deficits were characteristic of MSA, offering a potential imaging biomarker.
Conclusions:
- ECD-SPECT imaging demonstrates significant advantages over other techniques for assessing neurodegeneration in MSA.
- This method may assist clinicians in the accurate diagnostic characterization of patients with atypical parkinsonism, improving differential diagnosis.
